For the year ending 2025-12-31, ARCT made $82,031K in revenue. -$65,783K in net income. Net profit margin of -80.19%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue | 82,031 | 152,310 | ||
| Research and development, net | 112,212 | 195,156 | ||
| General and administrative | 46,079 | 52,823 | ||
| Total operating expenses | 158,291 | 247,979 | ||
| Loss from operations | -76,260 | -95,669 | ||
| Gain (loss) from foreign currency | 382 | -471 | ||
| Finance income, net | 10,095 | 15,195 | ||
| Net loss before income taxes | -65,783 | -80,945 | ||
| (benefit) provision for income taxes | - | -4 | ||
| Net loss | -65,783 | -80,941 | ||
| Comprehensive loss | -65,783 | -80,941 | ||
| Basic EPS | -2.4 | -3 | ||
| Diluted EPS | -2.4 | -3 | ||
| Basic Average Shares | 27,386,000 | 27,000,000 | ||
| Diluted Average Shares | 27,386,000 | 27,000,000 | ||
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT)